Last reviewed · How we verify
Aclacinomycin, Cytarabine
This combination of aclacinomycin and cytarabine works by intercalating into DNA and inhibiting DNA synthesis to kill rapidly dividing cancer cells.
This combination of aclacinomycin and cytarabine works by intercalating into DNA and inhibiting DNA synthesis to kill rapidly dividing cancer cells. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL).
At a glance
| Generic name | Aclacinomycin, Cytarabine |
|---|---|
| Sponsor | The First Hospital of Jilin University |
| Drug class | Chemotherapy combination (anthracycline + nucleoside analog) |
| Target | DNA (topoisomerase II for aclacinomycin; DNA polymerase for cytarabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Aclacinomycin is an anthracycline antibiotic that intercalates into DNA and generates reactive oxygen species, while cytarabine is a nucleoside analog that inhibits DNA polymerase and gets incorporated into DNA, causing chain termination. Together, they provide synergistic cytotoxic effects against leukemic cells through multiple mechanisms of DNA damage.
Approved indications
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Mucositis
- Cardiotoxicity (aclacinomycin-related)
- Hepatotoxicity
- Neurotoxicity (cytarabine-related)
Key clinical trials
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
- Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia (PHASE2)
- A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients (PHASE2)
- Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia (PHASE3)
- MRD Response-adapted Allo-HSCT for Adverse-risk AML (NA)
- Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (PHASE2)
- Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients (NA)
- Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aclacinomycin, Cytarabine CI brief — competitive landscape report
- Aclacinomycin, Cytarabine updates RSS · CI watch RSS
- The First Hospital of Jilin University portfolio CI